Back to Newsroom

Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease

SAN FRANCISCO, April 2, 2018​ – Symic Bio, a biopharmaceutical company developing novel
matrix-targeting biotherapeutics, today announced 12-month results from the Phase 1/2 SHIELD trial
evaluating SB-030 in patients with peripheral vascular disease undergoing angioplasty. Under an
extended trial protocol allowing assessment of secondary endpoint measurements at 12 months
following intervention, patients in the treatment group demonstrated a clinically meaningful and
statistically significant 23 percent reduction in index limb re-intervention as compared with the control
group (p=0.025).